Stryker
SYK NYSE· Health Care Equipment
Last close · Oct 26, 2026
$306.13
KIRA · Stoqly’s AI analyst, in plain words
- Stryker had $25.1B of revenue in fiscal 2025, up 11.2% on the year before. Over five years, revenue changed +11.8% a year on average.
- Its operating margin was 19.5%, up 3.1 pts: of every 100 in sales, about 19 is left after running the business.
- Stryker made $3.2B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 7.6% a year.
- Free cash flow was $4.3B in fiscal 2025, 17.1% of revenue.
- Stryker returned $1.3B to shareholders in fiscal 2025, 30% of free cash flow. The diluted share count rose 0.2%.
- Stryker owes $10.8B more than it holds in cash, about 1.7 years of operating profit.
Market cap
$118.2B
P/E
31.7x
Revenue
$25.1B
Net income
$3.2B
Free cash flow
$4.3B
Operating margin
19.5%
Stryker in 30 seconds · fiscal 2025
Are sales growing?
+11.2%
Yes. Sales grew 11.2% last year.
Does it make a profit?
12.9%
Yes. It keeps 12.9% of every sale as profit.
Does profit turn into cash?
17.1%
Yes. 17.1% of sales ends up as free cash.
Is debt under control?
1.7x
Keep an eye on it. Repaying its debt would take 1.7 years of operating profit.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
31.7x
One share costs 31.7 times its yearly profit per share. Typical for its sector: 27.9x.
What Stryker does
Stryker makes medical devices, mostly sold directly to doctors, hospitals and other healthcare facilities. Its products include surgical tools, endoscopy cameras, hospital beds and stretchers, defibrillators, stroke and blood-clot treatment devices, and joint replacement implants. It sells in about 61 countries through its own subsidiaries and through outside dealers and distributors. It says its products reach more than 150 million patients a year. It has two segments. MedSurg and Neurotechnology (instruments, endoscopy, medical, vascular and neuro cranial products) is the larger one by sales. Orthopaedics sells knee, hip, shoulder, trauma and extremity implants, including for use with its Mako robotic-arm system, now offered in more than 45 countries. Stryker says it competes in joint replacement mainly with Zimmer Biomet, Johnson & Johnson MedTech and Smith & Nephew, and names Medtronic and Olympus as rivals in other lines.
Biggest risks, in its own words
- Pricing pressure from health systems, insurers and governments that limit what they pay for devices.
- Intense competition, with new technology that could make its products obsolete.
- Shortages or price increases in materials and parts, including those it buys from a single supplier.
- Relying on independent distributors and on good relationships with healthcare professionals.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 11, 2026
- Legal name
- STRYKER CORP
- CIK
- 0000310764
Stryker · SYK
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $17.1B | $18.4B | $20.5B | $22.6B | $25.1B |
| Revenue growth | 19.2% | 7.8% | 11.1% | 10.2% | 11.2% |
| Gross margin | 64.1% | 62.8% | 63.7% | 63.9% | 64.0% |
| Operating margin | 15.1% | 15.4% | 19.0% | 16.3% | 19.5% |
| Net income | $2.0B | $2.4B | $3.2B | $3.0B | $3.2B |
| Net margin | 11.7% | 12.8% | 15.4% | 13.3% | 12.9% |
| Diluted EPS | $5.21 | $6.17 | $8.25 | $7.76 | $8.40 |
| Cash | |||||
| Cash from operations | $3.3B | $2.6B | $3.7B | $4.2B | $5.0B |
| Capital expenditure | $525M | $588M | $575M | $755M | $761M |
| Free cash flow | $2.7B | $2.0B | $3.1B | $3.5B | $4.3B |
| FCF margin | 16.0% | 11.0% | 15.3% | 15.4% | 17.1% |
| Dividends paid | $950M | $1.1B | $1.1B | $1.2B | $1.3B |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 0.5% | −0.0% | 0.4% | 0.5% | 0.2% |
| Debt and strength | |||||
| Cash and short-term investments | $3.0B | $1.9B | $3.1B | $3.7B | $4.1B |
| Debt incl. finance leases | $12.5B | $11.9B | $10.9B | $12.2B | $14.9B |
| Shareholders' equity | $14.9B | $16.6B | $18.6B | $20.6B | $22.4B |
| Net debt / EBITDA | 2.5x | 2.4x | 1.5x | 1.7x | 1.7x |
| Current ratio | 2.2x | 1.6x | 1.6x | 2.0x | 1.9x |
| Interest coverage | 7.7x | 8.4x | 10.7x | 9.0x | 8.1x |
| Returns and quality | |||||
| Return on capital | 9.5% | 9.8% | 12.7% | 11.4% | 11.3% |
| Return on equity | 14.3% | 15.0% | 18.0% | 15.3% | 15.1% |
| Piotroski F-score | 8 | 7 | 7 | 6 | 6 |
| Altman Z'' | 3.6 | 3.4 | 3.7 | 4.1 | 4.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$586M
8 insiders
Of sales under plans
0%
$1.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Stryker · SYK
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Stryker SYK | $118.2B | 11.2% | 19.5% | 17.1% | 11.3% | 31.7x | 6 |
| Becton Dickinson BDX | $54.0B | 8.2% | 11.8% | 12.2% | 5.5% | 59.2x | 6 |
| GE HealthCare GEHC | $32.9B | 4.8% | 13.4% | 7.3% | 13.3% | 17.2x | 7 |
| Boston Scientific BSX | $67.2B | 19.9% | 18.0% | 18.2% | 9.6% | 18.5x | 7 |
| Medtronic MDT | $121.8B | 8.4% | 17.8% | 14.9% | 7.7% | 23.3x | 7 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $306.13 a share, the company is worth $118.2B: 31.7 times its earnings of the last four quarters.
Stryker grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 3 of 4.
Source: SEC EDGAR XBRL filings (CIK 0000310764). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.